Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Rheumatoid Arthritis

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Semin Arthritis Rheum

Raskin N, Hiligsmann M, Rebutoc AR, Bansback N, Boonen A, Buchbinder R, Falahee M, Fraenkel L, Marshall DA, Maxwell L, Nieuwlaat R, Proulx L, Saadat P, Shea B, Tugwell P, Wiercioch W, Beaton D, Richards P, Schünemann H, Guillemin F, Hazlewood GS

doi: 10.1016/j.semarthrit.2025.152769

Further Publications Rheumatology

Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis-data from a Portuguese registry

Rheumatology (Oxford)

Silva SP, Monteiro B, Pinto Oliveira C, Pereira da Costa R, Matos CO, Lopes MD, Gomes CM, Bernardes M, Santos ME, Gago L, Abreu C, Fraga V, Mendes B, Lucas Rocha M, Soares CD, Silva C, Santos H, Valente P, Silva L, Eugénio G, Barcelos A

doi: 10.1093/rheumatology/keaf176

Rheumatoid Arthritis

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Arthritis Res Ther

Ramien R, Rudi T, Alten R, Krause A, Schneider M, Schaefer M, Strangfeld A, Meissner Y

doi: 10.1186/s13075-024-03449-9

Rheumatoid Arthritis

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Ann Rheum Dis

Wientjes MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, Boers M, Hooijberg F, Rispens T, de Vries A, van Vollenhoven RF, Ramiro S, van Herwaarden N, van den Bemt BJF, den Broeder AA

doi: 10.1016/j.ard.2025.03.015

Rheumatoid Arthritis

Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: Final results from the RA-BEYOND study

J Rheumatol

Edwards CJ, Krönke G, Avouac J, Li Z, Conti F, Balsa A, Mo D, Haladyj E, Fischer P, Tanaka M, Takita Y, Hagimori K, Takeuchi T

doi: 10.3899/jrheum.2024-0906

Rheumatoid Arthritis

Risk of total and cause-specific mortality in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis

Rheumatology (Oxford)

Zhang Q, Qi Y, Wang X, McDermott GC, Chang SH, Chaballa M, Khaychuk V, Paudel ML, Sparks JA

doi: 10.1093/rheumatology/keaf380

Rheumatoid Arthritis

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Ann Rheum Dis

Schaefer M, Purschke A, Zietemann V, Rudi T, Meissner Y, Richter A, Berger S, Rockwitz K, Krüger K, Schneider KM, Regierer AC, Strangfeld A

doi: 10.1016/j.ard.2025.05.014

Further Publications Rheumatology

Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer

Ann Rheum Dis

Sebbag E, Molina-Collada J, Ndoye R, Aletaha D, Askling J, Gente K, Bertheussen H, Bitoun S, Bolek EC, Buch MH, Burmester GR, Canhão HM, Chatzidionysiou K, Curtis JR, Danlos FX, Guimarães V, Hetland ML, Iannone F, Kostine M, Kragstrup TW, Kvien TK, Regierer AC, Schulze-Koops H, Sedmak N, Silva-Fernández L, Szekanecz Z, Lauper K, Finckh A, Gottenberg JE

doi: 10.1136/ard-2024-225981

Related content

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis-data from a Portuguese registry

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: Final results from the RA-BEYOND study

Risk of total and cause-specific mortality in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer